PMID

Data

Article Title

Organization

Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting thea

Universit£ degli Studi di Parma

Exploring

University of California San Francisco

Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaVß3 anda5ß1 integrin ligands.

University of Florence

Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.

Philipps-Universit£t Marburg

Targeting integrinsavß3 anda5ß1 with newß-lactam derivatives.

University of Bologna

Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.

Technische Universit£t M£nchen

Small Macrocycles As Highly Active Integrin?2?1 Antagonists.

Sanofi R & D

Synthesis and in vitro evaluation of a novel radioligand foravß3 integrin receptor imaging: [18F]FPPA-c(RGDfK).

University Hospital of Geneva

Modulation ofavß3- anda5ß1-integrin-mediated adhesion by dehydro-ß-amino acids containing peptidomimetics.

University of Bologna

Arylsulfonamide pyrimidines as VLA-4 antagonists.

Elan Pharmaceuticals, Inc.

Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.

Technische Universit£t M£nchen

SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.

Jerini AG

Discovery of orally available integrin alpha5beta1 antagonists.

Jerini AG

Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.

Merck Research Laboratories

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.

AstraZeneca

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.

AstraZeneca

Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.

Universita degli Studi di Bologna

Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.

Millennium Pharmaceuticals

Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.

Universit£ di Parma

Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.

3-Dimensional Pharmaceuticals Inc

Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.

Genentech Inc

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.

Merck Research Laboratories

Ultrasmall particle of iron oxide--RGD peptidomimetic conjugate: synthesis and characterisation.

Universit£ Catholique de Louvain

Multiple N-methylation by a designed approach enhances receptor selectivity.

Technische Universität München

Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.

Università di Bologna

Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.

Jerini AG

Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.

Università di Napoli Federico II

Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.

Johnson and Johnson Pharmaceutical Research & Development

Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.

RIKEN Discovery Research Institute

Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.

Nerviano

Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.

Pharmaceutical Research Institute

Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide.

Kyowa Hakko Kogyo Co., Ltd

Tuning the Biological Activity of RGD Peptides with Halotryptophans?.

Bielefeld University

Nonpeptide RGD antagonists: a novel class of mimetics, the 5,8-disubstituted 1-azabicyclo[5.2.0]nonan-2-one lactam.

University of Montpellier

Thiophene-based vitronectin receptor antagonists.

Shire BioChem Inc

Dual antagonists of ?5?1/?v?1 integrin for airway hyperresponsiveness.

University of California San Francisco

New ?-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.

University of Bologna

Design and synthesis of potent and selective inhibitors of integrin VLA-4.

Novartis Institute for BioMedical Research

Novel cilengitide-based cyclic RGD peptides as ?v?

Division of Organic Chemistry CSIR-National Chemical Laboratory (NCL)

2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.

Taisho Pharmaceutical Co., Ltd

Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.

Celltech Chiroscience

Selective Targeting of Integrin ?v?8 by a Highly Active Cyclic Peptide.

Technische Universit£t M£nchen

Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.

Biogen Inc

Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.

Bielefeld University

Could Dissecting the Molecular Framework of ?-Lactam Integrin Ligands Enhance Selectivity?

University of Bologna

Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.

DuPont Pharmaceuticals Company

Dehydro-?-proline Containing ?4?1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.

University of Bologna

Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.

University of Bradford

Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.

Merck Research Laboratories

Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.

Telios Pharmaceuticals, Inc.

Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic ?

University of Strathclyde

Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.

Universit£ degli Studi di Napoli "Federico II"

Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins.

University of Strathclyde

Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.

Merck Research Laboratories